Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Achilles Therapeutics plc Market Cap
The Achilles Therapeutics plc (ACHL) share price is expected to increase by 185.86% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered ACHL. Price targets range from $0.5 at the low end to $6 at the high end. The current analyst consensus for ACHL is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned ACHL 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Achilles Therapeutics plc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ACHL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ACHL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Geulah Livshits Chardan Capital | Buy | $6 | Maintains | Apr 5, 2024 |
| Joseph Catanzaro Piper Sandler | Neutral | $2 | Downgrade | Apr 5, 2024 |
| Tazeen Ahmad B of A Securities | Underperform | $0.5 | Downgrade | Dec 14, 2023 |
| Geulah Livshits Chardan Capital | Buy | $11 | Reiterates | Aug 7, 2023 |
| Geulah Livshits Chardan Capital | Buy | $11 | Maintains | May 11, 2023 |
| Joseph Catanzaro Piper Sandler | Overweight | $8 | Maintains | Dec 7, 2022 |
| Geulah Livshits Chardan Capital | Buy | $17 | Maintains | Dec 7, 2022 |
| Joseph Catanzaro Piper Sandler | Overweight | $25 | Initiates | Apr 26, 2021 |
| Geulah Livshits Chardan Capital | Buy | $27 | Initiates | Apr 26, 2021 |
B of A Securities | Buy | $20 | Initiates | Apr 26, 2021 |
| Mark Breidenbach Oppenheimer | Outperform | $23 | Initiates | Apr 26, 2021 |
| Eric Joseph JP Morgan | Underweight | $11 | Initiates | Apr 26, 2021 |
When did it IPO
2020
Staff Count
204
Country
United Kingdom
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Iraj Ali Ph.D.
Market Cap
$41.7M
In 2023, ACHL generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ACHL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 23 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Achilles Therapeutics PLC (ACHL) and Butterfly Network, Inc. (BFLY) have shown performance metrics this year, compared to their respective sectors.
Why It Matters - The performance of ACHL and BFLY relative to their sector indicates market sentiment and potential growth opportunities, influencing investment decisions and portfolio strategies.
Thu, 19 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Achilles Therapeutics is discontinuing its TIL-based cNeT therapy and closing Phase I/IIa trials. The company reported a cash position of $95.1 million as of June 30, 2024, and has engaged BofA Securities for strategic financial advice.
Why It Matters - Achilles' discontinuation of its cNeT therapy and clinical trials signals a setback in its pipeline, potentially impacting future revenue and investor confidence. Strategic financial advice may indicate an upcoming restructuring.
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Achilles announced a research collaboration with Arcturus Therapeutics to develop second-generation mRNA cancer vaccines utilizing AI-powered, tumor-targeting technology.
Why It Matters - The collaboration may enhance Achilles' innovation in cancer treatment, potentially leading to breakthroughs that can drive stock value and market competitiveness.
Wed, 22 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Achilles and Arcturus have formed a research collaboration to integrate Achilles' AI-driven tumor-targeting technology with Arcturus' self-amplifying mRNA platform.
Why It Matters - The collaboration enhances potential for innovative cancer therapies, likely boosting market competitiveness and attracting investor interest in both companies' futures.
Fri, 17 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Achilles ADSs will remain listed on the Nasdaq Global Select Market, and the company's operations are unaffected by the receipt of a regulatory notice.
Why It Matters - Achilles ADSs maintaining Nasdaq listing indicates stability, potentially reassuring investors about company health and market confidence, which can influence stock performance.
Wed, 08 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Achilles Therapeutics announced interim Phase I/IIa results for its T cell therapies in NSCLC and melanoma. The company has $112.3M in cash, funding operations through 2025, with further data expected in 2H 2024.
Why It Matters - Achilles Therapeutics' updates on clinical trials and strong cash position indicate potential for future growth and stability, making it a key player in the biopharmaceutical sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
